Hana Safah, MD, and Corey Cutler, MD, MPH, review recent data in graft-vs-host disease and provide comprehensive insights on treatment practices.
EP. 1: Overview of Graft-vs-Host Disease (GvHD)
Experts on graft-vs-host disease (GvHD) introduce themselves and provide an overview of GvHD, highlighting diagnosis, symptoms, risk stratification, and prevention.
EP. 2: How Does GvHD Typically Present?
Hematologist-oncologists Corey Cutler, MD, MPH, and Hana Safah, MD, discuss how graft-vs-host disease presents and the importance of early intervention.
EP. 3: Role of Biomarkers in Graft-vs-Host Disease
Corey Cutler, MD, MPH, discusses the role of prognostic markers in graft-vs-host disease and how they can potentially inform treatment selection.
EP. 4: Staging Practices for Chronic Graft-vs-Host Disease
Hana Safah, MD, reviews the NIH staging system for graft-vs-host disease and discusses the importance of staging in determining prognosis and informing treatment decisions.
EP. 5: First-Line Therapy for Chronic GvHD
Hematologist-oncologists discuss the first-line treatment options for patients with chronic GvHD and the advantages and disadvantages of steroids.
EP. 6: Treating Patients With Steroid-Refractory Chronic GvHD
Drs Safah and Cutler discuss treatment practices for patients with steroid-refractory graft-vs-host disease and highlight patients who are steroid dependent.
EP. 7: Approved Therapies for Steroid-Refractory Chronic GvHD
Hematologist-oncologists give an overview of the 3 approved treatment options for patients with steroid-refractory chronic GvHD—ruxolitinib, ibrutinib, and belumosudil—and highlight the REACH3 and ROCKstar studies.
EP. 8: Therapies in Development for Chronic GvHD
Drs Cutler and Safah look to the future of chronic GvHD treatment and discuss ongoing research, highlighting studies investigating axatilimab and abatacept.
EP. 9: Supportive Care and Medication Access in GvHD
Hana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC